REDDING, Calif., Sept. 16, 2024 /PRNewswire/ -- According to a new market research report titled, 'Lab Automation Market Size, Share, Forecast, &…
Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease1 New results show…
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically…
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at…
MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug…
AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology…
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing…
Survey results indicate that most organizations are planning to invest in AI within the next 1-3 years and are expecting AI…
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and…
University of California selects AI purchasing platform to accelerate scientific and research procurement for 10 campusesOAKLAND, Calif., Sept. 12, 2024…